BR112014003774A2 - inibidores de dyrk1 e usos dos mesmos - Google Patents
inibidores de dyrk1 e usos dos mesmosInfo
- Publication number
- BR112014003774A2 BR112014003774A2 BR112014003774A BR112014003774A BR112014003774A2 BR 112014003774 A2 BR112014003774 A2 BR 112014003774A2 BR 112014003774 A BR112014003774 A BR 112014003774A BR 112014003774 A BR112014003774 A BR 112014003774A BR 112014003774 A2 BR112014003774 A2 BR 112014003774A2
- Authority
- BR
- Brazil
- Prior art keywords
- dyrk1
- inhibitors
- dyrk1 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11178190 | 2011-08-19 | ||
| EP11178190.2 | 2011-08-19 | ||
| PCT/EP2012/066151 WO2013026806A1 (en) | 2011-08-19 | 2012-08-17 | Dyrk1 inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014003774A2 true BR112014003774A2 (pt) | 2017-03-07 |
| BR112014003774B1 BR112014003774B1 (pt) | 2021-12-14 |
Family
ID=46704656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014003774-4A BR112014003774B1 (pt) | 2011-08-19 | 2012-08-17 | Inibidores de dyrk1 e usos dos mesmos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9446044B2 (pt) |
| EP (1) | EP2744797B1 (pt) |
| JP (1) | JP6017559B2 (pt) |
| KR (1) | KR102006749B1 (pt) |
| CN (1) | CN103797002B (pt) |
| AU (1) | AU2012298510B2 (pt) |
| BR (1) | BR112014003774B1 (pt) |
| CA (1) | CA2848896C (pt) |
| DK (1) | DK2744797T3 (pt) |
| EA (1) | EA026377B1 (pt) |
| ES (1) | ES2551268T3 (pt) |
| HK (1) | HK1198827A1 (pt) |
| IL (1) | IL230917A (pt) |
| PL (1) | PL2744797T3 (pt) |
| PT (1) | PT2744797E (pt) |
| WO (1) | WO2013026806A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015534584A (ja) * | 2012-10-10 | 2015-12-03 | フェリシテックス・セラピューティクス，インコーポレイテッド | 静止癌細胞の標的化による癌の治療 |
| FR3002044A1 (fr) * | 2013-02-08 | 2014-08-15 | Centre Nat Rech Scient | Marqueur dyrk1a pour la maladie d'alzheimer |
| CA2854542A1 (en) | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| JP2015107945A (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| CA2997556C (en) * | 2015-09-03 | 2020-12-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
| JP7278776B2 (ja) * | 2016-04-15 | 2023-05-22 | フェリシテックス・セラピューティクス，インコーポレイテッド | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ |
| MX2018012511A (es) * | 2016-04-15 | 2019-07-08 | Felicitex Therapeutics Inc | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. |
| WO2018119039A1 (en) | 2016-12-23 | 2018-06-28 | Felicitex Therapeutics, Inc. | Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases |
| CA3084581A1 (en) | 2017-11-20 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| JP2021510153A (ja) | 2018-01-05 | 2021-04-15 | アイカーン スクール オブ メディシン アット マウント サイナイ | 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物 |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN113164476A (zh) * | 2018-09-28 | 2021-07-23 | 代表亚利桑那大学的亚利桑那校董会 | Dyrk1/clk的小分子抑制剂及其用途 |
| CN113543783A (zh) * | 2018-12-31 | 2021-10-22 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| JPWO2021153665A1 (pt) * | 2020-01-30 | 2021-08-05 | ||
| WO2022059778A1 (ja) * | 2020-09-18 | 2022-03-24 | カルナバイオサイエンス株式会社 | 環状ウレア誘導体 |
| CA3191617A1 (en) * | 2020-09-18 | 2022-03-24 | Sumitomo Pharma Co., Ltd. | Novel amine derivatives |
| JPWO2023008470A1 (pt) * | 2021-07-28 | 2023-02-02 | ||
| WO2023008472A1 (ja) * | 2021-07-28 | 2023-02-02 | カルナバイオサイエンス株式会社 | 新規ベンゾチアゾール誘導体 |
| WO2023140846A1 (en) * | 2022-01-20 | 2023-07-27 | Felicitex Therapeutics, Inc. | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| GB0705566D0 (en) | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
| FR2943057B1 (fr) * | 2009-03-12 | 2011-06-03 | Centre Nat Rech Scient | DERIVES DE 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO°2,1-a!ISOINDOL-6(10bH)- ONES, LEUR PROCEDE DE PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES |
| WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
-
2012
- 2012-08-17 CN CN201280040405.7A patent/CN103797002B/zh active Active
- 2012-08-17 ES ES12748470.7T patent/ES2551268T3/es active Active
- 2012-08-17 WO PCT/EP2012/066151 patent/WO2013026806A1/en active Application Filing
- 2012-08-17 PL PL12748470T patent/PL2744797T3/pl unknown
- 2012-08-17 EA EA201400245A patent/EA026377B1/ru not_active IP Right Cessation
- 2012-08-17 BR BR112014003774-4A patent/BR112014003774B1/pt active IP Right Grant
- 2012-08-17 JP JP2014525468A patent/JP6017559B2/ja active Active
- 2012-08-17 PT PT127484707T patent/PT2744797E/pt unknown
- 2012-08-17 EP EP12748470.7A patent/EP2744797B1/en active Active
- 2012-08-17 US US14/238,925 patent/US9446044B2/en active Active
- 2012-08-17 KR KR1020147007325A patent/KR102006749B1/ko active IP Right Grant
- 2012-08-17 DK DK12748470.7T patent/DK2744797T3/en active
- 2012-08-17 CA CA2848896A patent/CA2848896C/en active Active
- 2012-08-17 AU AU2012298510A patent/AU2012298510B2/en active Active
-
2014
- 2014-02-11 IL IL230917A patent/IL230917A/en active IP Right Grant
- 2014-12-05 HK HK14112274.6A patent/HK1198827A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012298510A1 (en) | 2014-04-10 |
| US9446044B2 (en) | 2016-09-20 |
| EA201400245A1 (ru) | 2014-07-30 |
| CA2848896A1 (en) | 2013-02-28 |
| KR102006749B1 (ko) | 2019-08-02 |
| EP2744797A1 (en) | 2014-06-25 |
| IL230917A0 (en) | 2014-03-31 |
| WO2013026806A1 (en) | 2013-02-28 |
| CA2848896C (en) | 2019-10-29 |
| JP2014525928A (ja) | 2014-10-02 |
| JP6017559B2 (ja) | 2016-11-02 |
| CN103797002B (zh) | 2017-02-22 |
| CN103797002A (zh) | 2014-05-14 |
| US20140275064A1 (en) | 2014-09-18 |
| EP2744797B1 (en) | 2015-09-09 |
| AU2012298510B2 (en) | 2016-10-27 |
| PL2744797T3 (pl) | 2016-01-29 |
| EA026377B1 (ru) | 2017-04-28 |
| ES2551268T3 (es) | 2015-11-17 |
| KR20140057614A (ko) | 2014-05-13 |
| DK2744797T3 (en) | 2015-10-19 |
| HK1198827A1 (en) | 2015-06-12 |
| IL230917A (en) | 2017-02-28 |
| PT2744797E (pt) | 2015-11-16 |
| BR112014003774B1 (pt) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014003774A2 (pt) | inibidores de dyrk1 e usos dos mesmos | |
| BR112013033098A2 (pt) | inibidores de glicosidade seletivos e usos dos mesmos | |
| BR112013013167A2 (pt) | inibidores de bromodomínio e usos dos mesmos | |
| BR112013021524A2 (pt) | micro-organismos recombinantes e usos dos mesmos | |
| BR112013029163A2 (pt) | modulação quinase e indicações dos mesmos | |
| SMT201500271B (it) | Inibitori di neprilisina | |
| BR112013007499A2 (pt) | piridazinonas - métodos de criação e usos | |
| BR112014030410A2 (pt) | inibidores de pirazolopirimidona e pirazolopiridona de tanquirase | |
| CR20120576A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| CR20140147A (es) | Inhibidores de aplicación viral | |
| DK3329919T3 (da) | Acc-inhibitorer og anvendelser deraf | |
| DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| DK2920168T3 (da) | Heterocykliske glutaminase-inhibitorer | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| DK2895484T3 (da) | Glucosylceramidsynthase-inhibitorer | |
| BR112014003655A2 (pt) | dispositivo cirúrgico | |
| BR112013022949A2 (pt) | dispositivo e métodos de microagulha | |
| CO6990717A2 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| BR112013022955A2 (pt) | dispositivo e métodos de microagulha | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| BR112014001991A2 (pt) | certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos | |
| BR112013014235A2 (pt) | anticorpos anti-ccr4 e usos dos mesmos | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112013024493A2 (pt) | cristais de anticorpo antiesclerostina e formulações dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2012, OBSERVADAS AS CONDICOES LEGAIS. |